• News
  • SAN DIEGO
  • BioTech

Ligand inks deal with Omthera Pharma

San Diego-based Ligand Pharmaceuticals (Nasdaq: LGND) has signed a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca (NYSE: AZN), for the development of products to treat dyslipidemia, a high concentration of cholestorol, fat or other lipids in the blood.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11085 N. Torrey Pines Rd. Ste., 300
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
72.95
  2.65  
+ 3.77%
253,009,000
79.61
41.99

Insider Trade Data

Date Insider Shares Type Value
03/19/2015 Patel, Sunil 4,591 Sell $341,662
03/16/2015 Berkman, Charles S 11,264 Sell $839,649
03/16/2015 Berkman, Charles S 5,264 Exchange $106,939
03/16/2015 Berkman, Charles S 11,264 Sell $839,649
03/16/2015 Berkman, Charles S 5,264 Exchange $106,939

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
Subscribe Today!